Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status (Q34119518)

31 July 2017

title

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status (English)

1 reference

31 July 2017

0 references

Gottwald MD

1 reference

31 July 2017

Rozanski RI

series ordinal

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

1673-1682

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Changes in brain cholinesterases in senile dementia of Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Cholinergic markers in elderly patients with early signs of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Butyrylcholinesterase in the life cycle of amyloid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-(2-phthalimidoethyl)piperidine and related derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Effects of SDZ ENA 713, novel acetyl cholinesterase inhibitor, on learning of rats with basal forebrain lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1673

10.1517/13543784.8.10.1673

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference